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A new clinical study reported in the New England Journal of Medicine unveils the long-awaited outcome of
anti-CTLA-4 therapy for melanoma. It provides grounds for continued enthusiasm for cancer immuno-
therapy, deepens our thoughts on underlying mechanisms, and suggests exciting next steps.The immune system’s ability to recognize
and kill tumor cells has been appreciated
since William Coley, who suspected a
causal link between streptococcal infec-
tion and tumor regression in his patient,
‘‘therapeutically’’ infected those having
unresectable cancer with live or mixed
killed bacteria, and brought some actual
success more than a century ago (Coley,
1893). The cancer remission was thought
to occur because of the immunostimula-
tory effects of Coley’s inoculum. The
emerged concept of immunotherapy,
however, did not immediately rise to a
status in cancer treatment broadly com-
parable to surgery, radiotherapy, and
chemotherapy. However, immunotherapy
has been received with increasing enthu-
siasm with our better understanding of
tumor immunology.
Metastatic melanoma is one of the
most aggressive cancers and is also
highly refractory to conventional cancer
therapy. A recent report of a Phase 3 clin-
ical study assessing the efficacy and
adverse effects of ipilimumab (Hodi
et al., 2010) ushers in a new stage of
immune-based treatment of advanced
melanoma, and perhaps of cancer immu-
notherapy in general. Ipilimumab is a
fully human monoclonal antibody against
cytotoxic T lymphocyte-associated anti-
gen 4 (CTLA-4) that has shown promising
results in potentiating a tumor-specific
immune response and limiting metastatic
melanoma and other tumors (Fong and
Small, 2008). This new study of more
than 600 advanced melanoma patients
demonstrates that administration of the
antibody, either alone or in conjunction
with a peptide vaccine targeting themela-
noma-derived antigen gp100, signifi-
cantly extended overall survival whencompared to vaccine alone. Improve-
ments were seen in median survival and
survival 1 and 2 years posttreatment.
These are remarkable outcomes for mela-
noma clinical trials performed at a similar
scale and represent the culmination of
successful clinical translation of anti-
CTLA-4 therapy since its inception and
preclinical investigation by Allison and
colleagues (Leach et al., 1996).
How does CTLA-4 blockade lead to
tumor regression? The T cell-mediated
immune response, including to tumors,
kicks in when antigens are displayed
to T cells by antigen-presenting cells
(APCs). In addition, APCs express CD80
and CD86 on their surface for binding
to CD28 on T cells to activate costimula-
tory signal, which is crucial for the induc-
tion of T cell proliferation and the onset
of T cell immunity. APC activation of
T cells is, however, subject to tight
regulation. CTLA-4, structurally akin to
CD28, is newly expressed on activated
T cells, and, with its higher affinity for
CD80 and CD86, replaces CD28 in
APC-T cell interactions (Teft et al., 2006).
Unlike CD28, CTLA-4 transmits an inhib-
itory intracellular signal in T cells to
dampen the antigen-induced biochem-
ical events. CTLA-4 expression is there-
fore important for limiting T cell activation
and preventing an exaggerated immune
response, but limits the T cell-mediated
immune response against tumors. Inter-
ference with CTLA-4 function thus
provides a point of targeting the immu-
nosuppressive environment of tumor-
bearing hosts.
The new study finds that the gp100
vaccine did not provide benefit beyond
the effects of ipilimumab alone (Hodi
et al., 2010), which suggests that inherentCancer Ctumor immunogenicity may be increased
to a clinically significant degree just by
unfettering host immunity from certain
endogenous regulatory mechanisms.
What was less certain is whether such
a boon would be granted without paying
too high a price. Patients treated with
ipilimumab manifested diverse immune-
related adverse events, ranging from
skin rashes to colitis, that were predict-
able from the action mechanism of the
therapy and were manageable in many
cases with steroid or anti-tumor necrosis
factor agents (Hodi et al., 2010). Regard-
less, immune-related side effects will
probably continue to be a major compli-
cation in using CTLA-4 antibodies for
cancer. Many questions arise regarding
the efficacy and adverse events of
potentiating immune responses in cancer
patients: Do antitumor immunity and
autoimmunity depend on the same
effector mechanisms of T cell immunity?
Could the immune side effects be allevi-
ated while preserving tumor-specific
immune responses? Would there be
a therapeutic window that differentiates
self-destructive and tumor-killing reac-
tions? The Phase 3 ipilimumab study
offered new promises and also empha-
sizes new questions and opportunities.
We see several pieces of new informa-
tion from mouse model studies that await
clinical investigation. There is little doubt
that CTLA-4 functions in drawing in
the reins of CD28 in antigen-stimulated
T cells. CTLA-4 is also expressed in
CD4+CD25+Foxp3+ regulatory T (Treg)
cells, which are a specific group of
T cells with potent and broad immuno-
suppressive activities and play a central
role in immune tolerance. This under-
standing prompted curiosity about theell 18, July 13, 2010 ª2010 Elsevier Inc. 9
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activated T cells and Treg cells. With
a conditional gene ablation strategy, it
was shown that mice lacking Treg cell-
specific CTLA-4 expression were prone
to spontaneous autoimmune disease,
albeit less severely than CTLA-4 null
mice (Wing et al., 2008). On the other
hand, restoration of CTLA-4 induction to
activated conventional T cells but not
Treg cells prevented infiltration of tissue-
damaging T cells in the gastrointestinal
and other vital tissues of CTLA-4 null
animals (Jain et al., 2010). These results
indicated that loss of CTLA-4 expression
in Treg cells alone was sufficient for
generation and aberrant activation of
self-reactive T cells, but a full-fledged
autoimmune disease still relied on
CTLA-4 acting in cis in activated conven-
tional T cells. Importantly, with mice
expressing human instead of mouse
CTLA-4 in specific subsets of T cells
(therefore selectively targeted by a human
CTLA-4-directed antibody), it was dem-
onstrated that CTLA-4 blockade in
conventional T cells is more important
for inducing immune-mediated tumor
regression, but maximal antitumor
responses occurred only when the anti-
body was allowed to target both conven-
tional T cells and Treg cells (Peggs et al.,
2009). Taken together, these findings
illustrate the potential that CTLA-4-medi-
ated immunosuppressive mechanisms
can be dissected into distinct functional
modules depending on the cell types
and processes in which CTLA-4 is ex-
pressed and functioning.10 Cancer Cell 18, July 13, 2010 ª2010 ElsevHow does this work impact advanced
melanoma patients? The application of
CTLA-4 blockade seems destined to
become a new standard of care for these
patients, who otherwise have few options.
Although the current trial had required
patients to express HLA-A2 because of
its importance for gp100 responsiveness
(control arm), prior evidence suggested
that HLA-A2 should not be required for
efficacy of CTLA-4 blockade. The tail of
the survival curve suggests a subpopula-
tion for whom survival is significantly
durable. Which features (of tumor and/or
host) might predict efficacy or longevity
of response? What mechanism(s)
account for acquisition of resistance?
How might those mechanisms be thera-
peutically targeted?
Today the melanoma community is
bursting with excitement, both because
of this striking efficacy of ‘‘targeted immu-
notherapy’’ and because of additional
evidence of major clinical responses
with targeted kinase-inhibitor therapies
in advanced melanoma patients with
mutations in either c-Kit or BRAF.
Although these targeted approaches are
transforming the oncologist’s armamen-
tarium against advanced melanoma,
sustainable remission (i.e., cure) remains
painfully elusive. An obvious next step
is to combine these agents. Indeed,
recent preclinical data have shown
enhanced melanoma immunogenicity
upon BRAF(V600E) suppression (Boni
et al., 2010). The mutant-selective action
of several BRAF(V600E)-targeted agents
offers the key advantage of sparing MAPier Inc.kinase pathway activity within host
immune cells upon systemic drug admin-
istration. The ability of mechanism-based,
targeted molecular strategies to exhibit
major clinical efficacy in one of the most
aggressive human cancers is a massive
achievement. The opportunity to combine
such immune-targeted and oncoprotein-
targeted approaches is groundbreaking,
both for scientific advancement and
hopefully for patients.REFERENCES
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